These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28444983)

  • 1. Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension.
    Hjermitslev M; Grimm DG; Wehland M; Simonsen U; Krüger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):225-233. PubMed ID: 28444983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.
    Dudkowski C; Karim A; Zhao Z; Alonso AB; Garg D; Preston RA
    J Clin Pharmacol; 2018 Jan; 58(1):48-56. PubMed ID: 28750149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azilsartan medoxomil for the treatment of hypertension.
    Vasiliou S
    Drugs Today (Barc); 2011 Sep; 47(9):647-51. PubMed ID: 21971539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry.
    Gitt AK; Bramlage P; Potthoff SA; Baumgart P; Mahfoud F; Buhck H; Ehmen M; Ouarrak T; Senges J; Schmieder RE;
    BMC Cardiovasc Disord; 2016 Mar; 16():56. PubMed ID: 26956148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical evaluation of the efficacy and tolerability of azilsartan.
    De Caterina AR; Harper AR; Cuculi F
    Vasc Health Risk Manag; 2012; 8():299-305. PubMed ID: 22661897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azilsartan medoxomil: a review of its use in hypertension.
    Perry CM
    Clin Drug Investig; 2012 Sep; 32(9):621-39. PubMed ID: 22877322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azilsartan: Novel Angiotensin Receptor Blocker.
    Dargad RR; Parekh JD; Dargad RR; Kukrety S
    J Assoc Physicians India; 2016 Mar; 64(3):96-98. PubMed ID: 27731574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
    Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
    Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
    Kurtz TW; Kajiya T
    Vasc Health Risk Manag; 2012; 8():133-43. PubMed ID: 22399858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.
    Baker WL; White WB
    Ann Pharmacother; 2011 Dec; 45(12):1506-15. PubMed ID: 22116996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
    Sica D; White WB; Weber MA; Bakris GL; Perez A; Cao C; Handley A; Kupfer S
    J Clin Hypertens (Greenwich); 2011 Jul; 13(7):467-72. PubMed ID: 21762358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension.
    Angeli F; Verdecchia P; Pascucci C; Poltronieri C; Reboldi G
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):379-85. PubMed ID: 23387516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
    Barrios V; Escobar C
    Expert Opin Pharmacother; 2013 Nov; 14(16):2249-61. PubMed ID: 24070321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide.
    Neutel JM; Cushman WC; Lloyd E; Barger B; Handley A
    J Clin Hypertens (Greenwich); 2017 Sep; 19(9):874-883. PubMed ID: 28681550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.
    Bönner G; Bakris GL; Sica D; Weber MA; White WB; Perez A; Cao C; Handley A; Kupfer S
    J Hum Hypertens; 2013 Aug; 27(8):479-86. PubMed ID: 23514842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes.
    White WB; Cuadra RH; Lloyd E; Bakris GL; Kupfer S
    J Hypertens; 2016 Apr; 34(4):788-97. PubMed ID: 26766564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension.
    Kipnes MS; Handley A; Lloyd E; Barger B; Roberts A
    J Clin Hypertens (Greenwich); 2015 Mar; 17(3):183-92. PubMed ID: 25619410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Azilsartan Medoxomil Capabilities in Arterial Hypertension and Obesity].
    Vasyuk YA; Shupenina EY; Nesvetov VV; Nesterova EA; Golubkova EI
    Kardiologiia; 2016 Dec; 56(11):108-112. PubMed ID: 28290827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.